Altimmune (NASDAQ:ALT), Inc. provided a detailed update on its clinical trials and financial performance during its Third Quarter 2023 Financial Results Conference Call. The...
Investing.com - Altimmune (NASDAQ: ALT) reported third quarter EPS of $-0.39, $0.06 better than the analyst estimate of $-0.45. Revenue for the quarter came in at $362K versus the...
Investing.com - Altimmune (NASDAQ: ALT) reported second quarter EPS of $-0.32, $0.15 better than the analyst estimate of $-0.47. Revenue for the quarter came in at $6K versus the...
Investing.com - Altimmune (NASDAQ: ALT) reported first quarter EPS of $-0.40, $0.10 better than the analyst estimate of $-0.50. Revenue for the quarter came in at $21K versus the...
By Michael Erman NEW YORK (Reuters) - The enormous demand for weight-loss treatments like Novo Nordisk’s Wegovy could support as many as 10 competing products with annual sales...
By Michael Erman NEW YORK (Reuters) -The enormous demand for weight-loss treatments like Novo Nordisk’s Wegovy could support as many as 10 competing products with annual sales...
By Vlad Schepkov Shares of Viking Therapeutics (NASDAQ:VKTX) are trading down over 15% late into Tuesday's session, in a move linked to the disappointing clinical data posted by...
Clinical trials and results seem very positive but the stock is tanking. Help me... cheers.
0
Anyone around?
0
I've seen this one before, it looks like a come back but when I buy it, it goes down to a dollar. I'm not buying it though so it will probably do great ;o)
1
lol. i would recommend you buy the stock and put in a stop loss to limit the potential damage for a speculative stock like this. i believed in this comeback early, so i bought in a month ago at 9. its been a nice run. i am now expecting a little pause, so i may sell some short term calls to take in a little profit.